Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate
Autism Research · 2025
DOI: 10.1002/aur.70151 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Autism Research, 2025. Verfasst von Karla C M Costa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil. Hauptthemen laut MEDLINE: Valproic Acid, Cannabidiol, Behavior, Animal, Risperidone. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, INCT 2014: Translational Medicine.
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits, repetitive behaviors, and sensory abnormalities. Sodium valproate (VPA) exposure during embryonic development is a well‐established preclinical model for ASD, leading to increased oxidative stress in the developing brain, including lipid peroxidation, which affects cell proliferation and organization. This study aimed to investigate the potential therapeutic effects of cannabidiol (CBD) and risperidone (RISP) in reversing ASD‐like behaviors and associated neurobiological alterations induced by embryonic VPA exposure in a zebrafish model. Zebrafish embryos were exposed to 125 μM VPA for 2 days post‐fertilization (dpf). At 3–4 dpf, embryos were treated with 0.06 μM CBD or 1 μM RISP. Behavioral assays were conducted to assess hyperlocomotion and aggressive behavior. At 7 dpf, lipid peroxidation levels were measured, and expression of glial fibrillary acidic protein (GFAP) and calcium/calmodulin (CaM) were analyzed to evaluate neurobiological changes. VPA exposure resulted in increased hyperlocomotion and aggression. CBD treatment effectively reversed these behaviors, while RISP showed limited efficacy. Additionally, CBD reduced lipid peroxidation and restored anandamide levels, whereas RISP did not exhibit these effects. CBD also normalized GFAP and CaM expression, indicating restoration of glial function and excitatory/inhibitory balance. CBD demonstrated a better efficacy and safety profile compared to RISP in reversing ASD‐like behaviors and associated neurobiological alterations in the zebrafish model. These findings suggest that CBD may offer a safer and more effective therapeutic alternative for managing ASD‐related symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Center for Cannabinoid Research, Mental Health Building, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
- Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, SP, Brazil.
- National Institute of Science and Technology for Translational Medicine (INCT TM), CNPQ/FAPESP/CAPES, Ribeirão Preto, SP, Brazil.
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, SP, Brazil.
- Laboratory of Psychiatric Neuroimaging (LIM21), Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo, SP, Brazil.
ORCID-Profile: Karla C M Costa, Tamires A V Brigante, Alline C Campos
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- INCT 2014: Translational Medicine
Zitieren
APA
Costa, K. C. M., Brigante, T. A. V., Lirio, P. H. C., Fernandes, G. G., Scarante, F. F., Scomparin, D. S., Ferreira, R. R., Vicente, M. A., Abe, F. R., Guimarães, F. S., Hallak, J. E. C., Crippa, J. A., de Oliveira, D. P., & Campos, A. C. (2025). Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate. Autism Research. https://doi.org/10.1002/aur.70151
Vancouver
Costa KCM, Brigante TAV, Lirio PHC, Fernandes GG, Scarante FF, Scomparin DS, et al. Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate. Autism Research. 2025. doi:10.1002/aur.70151
BibTeX
@article{Costa2025,
author = {Costa, Karla C M and Brigante, Tamires A V and Lirio, Pedro H C and Fernandes, Gabriel G and Scarante, Franciele F and Scomparin, Davi S and Ferreira, Rafael R and Vicente, Maria A and Abe, Flavia R and Guimarães, Francisco S and Hallak, Jaime E C and Crippa, Jose A and de Oliveira, Danielle P and Campos, Alline C},
title = {Comparative Analysis of Cannabidiol and Risperidone on Behavioral and Neurochemical Outcomes, and Neurodevelopment Markers in a Zebrafish Model of Embryonic Exposure to Sodium Valproate},
journal = {Autism Research},
year = {2025},
doi = {10.1002/aur.70151}
}
EUVIMED